Chronic Obstructive Pulmonary Disease News and Research RSS Feed - Chronic Obstructive Pulmonary Disease News and Research

The World Health Organisation (WHO) has described Chronic Obstructive Pulmonary Disorder (COPD) as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.
LAMA/LABA combination better than monotherapy for severe COPD

LAMA/LABA combination better than monotherapy for severe COPD

Combination treatment with umeclidinium bromide and vilanterol offers clinically meaningful improvements over tiotropium monotherapy for patients with moderate-to-very severe chronic obstructive pulmonary disease, study data show. [More]
Combination therapy beneficial for COPD patients

Combination therapy beneficial for COPD patients

Research published in JAMA supports the use of a combination of long-acting β-agonists and inhaled corticosteroids in patients with chronic obstructive pulmonary disease. [More]
Severe childhood asthma linked to COPD in adult life

Severe childhood asthma linked to COPD in adult life

Children with severe asthma are at an increased risk of developing chronic obstructive pulmonary disease in adult life, show findings of an Australian study. [More]
Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control, 79 percent of tumors, for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. [More]
Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation. [More]
First-ever evidence-based guidelines released for prevention of acute COPD exacerbations

First-ever evidence-based guidelines released for prevention of acute COPD exacerbations

The American College of Chest Physicians (CHEST) and the Canadian Thoracic Society (CTS) announced today the release of Prevention of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: American College of Chest Physicians and Canadian Thoracic Society Guideline in the journal CHEST. [More]
Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). [More]
International Biophysics files patent protection for revolutionary AffloVest

International Biophysics files patent protection for revolutionary AffloVest

International Biophysics Corporation of Austin, Texas announces its filing of U.S. patent protection for its revolutionary AffloVest. The company has also recently confirmed exclusive ownership rights concerning the manufacture, sale and distribution of the AffloVest in its markets. [More]
Researchers are developing compounds to combat causative agents of periodontitis

Researchers are developing compounds to combat causative agents of periodontitis

A total 12 million Germans suffer from periodontitis. If the inflammation remains untreated, this could lead to tooth loss. However, it is also suspected of triggering many other diseases, like cardiopulmonary diseases. Researchers are studying the interactions, and developing compounds to combat the causative agents. [More]
Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. [More]
Study demonstrates longer-term benefits of Lung Flute for COPD patients

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Patients with chronic obstructive pulmonary disease (COPD) report improved symptoms and health status when they use a hand-held respiratory device called the Lung Flute-, according to a new study by the University at Buffalo. Usually caused by smoking, COPD, which includes chronic bronchitis and emphysema, is the third leading cause of death in the U.S. [More]
Researchers examine how telephone-based coaching could help COPD patients

Researchers examine how telephone-based coaching could help COPD patients

Coaching patients with chronic obstructive pulmonary disease to manage stress, practice relaxation and participate in light exercise can boost a patient's quality of life and can even improve physical symptoms, researchers at Duke Medicine report. [More]
Pneumonia in COPD patients has distinct clinical features

Pneumonia in COPD patients has distinct clinical features

The aetiology and clinical features of community-acquired pneumonia are different in people with chronic obstructive pulmonary disease than in those without the lung condition, Spanish research demonstrates. [More]
Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Lobectomy and anatomic segmentectomy appear to offer similar perioperative and oncological outcomes in patients with stage I non-small-cell lung cancer, analysis suggests. [More]
LABA-ICS combination therapy better than LABAs alone for COPD

LABA-ICS combination therapy better than LABAs alone for COPD

Among older adults with chronic obstructive pulmonary disease (COPD), particularly those with asthma, newly prescribed long-acting beta-agonists (LABAs) and inhaled corticosteroid combination therapy, compared with newly prescribed LABAs alone, was associated with a lower risk of death or COPD hospitalization, according to a study in the September 17 issue of JAMA. [More]
Parion Sciences receives $3 million CFFT award to support development of new CF treatment

Parion Sciences receives $3 million CFFT award to support development of new CF treatment

Parion Sciences today announced it has received a $3 million award from Cystic Fibrosis Foundation Therapeutics to support the development of P-1037, Parion's new investigational treatment for cystic fibrosis (CF). [More]
Researchers explain why people with asthma have hard time dealing with respiratory viruses

Researchers explain why people with asthma have hard time dealing with respiratory viruses

People with asthma often have a hard time dealing with respiratory viruses such as the flu or the common cold, and researchers have struggled to explain why. [More]
New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma. [More]
LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced nearly $750,000 in Proof of Concept grants to Washington state for-profit and non-profit organizations to promote translation of health-related technologies from the laboratory to the commercial marketplace. [More]
Professor receives grant from NIH to test effects of high-intensity functional training

Professor receives grant from NIH to test effects of high-intensity functional training

Katie Heinrich, assistant professor of kinesiology at Kansas State University, has been awarded an investigator-initiated grant from the National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases for more than $2.52 million. [More]